Sensitivity analyses with additional adjustments for ketone bodies, FLI, HSI, HOMA‐IR, the inflammation markers GlycA and hs‐CRP, and comorbidities asthma or COPD, rheumatic disease, and a history of malignancy are shown in Table S7. This evidence concerns the gene MAP3K14 and chronic obstructive pulmonary disease.